This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
Name: Hydroxychloroquine (HCQ)
Name: Vemurafenib (VEM)
Single Group Assignment
There is one SNP
- Patients must have histologically confirmed diagnosis of Stege IV metastic melanoma positive for BRAF V600E mutation by either the COBAS test or other CLIA approved assay. --- V600E ---